In this episode, our host Maryam Tabatabai is joined by three guests Olivia Pane, PharmD; Dr. Edmundo Rodriguez Frias; and Katie Lockhart, who unpack insights from Prime Therapeutics’ latest clinical report that dives into the latest evidence-based clinical insights related to the rising prevalence and significant health impact of metabolic dysfunction-associated steatohepatitis, or MASH. MASH is a silent but serious liver condition affecting over 22 million Americans, with numbers projected to rise sharply by 2030.

Listeners learn about the latest major development in liver health treatment: the FDA approval of Novo Nordisk’s semaglutide – Wegovy -- as the first GLP-1 drug indicated for MASH. We explore how this development may revolutionize care and could offer a more affordable alternative to treating this condition.

The Evolution of GLP-1s
www.primetherapeutics.com
All Pharmacy Friends episodes

Metabolic dysfunction-associated steatohepatitis (MASH) – A new era in liver health

The views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice